These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 24851652)

  • 1. Giving information on medicinal products to the general public--in search of a definition to safeguard the patient.
    Faeh A
    Eur J Health Law; 2014 Apr; 21(2):176-95. PubMed ID: 24851652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DTCA of prescription medicines in the European Union: is there still a need for a ban?
    Poser M
    Eur J Health Law; 2010 Dec; 17(5):471-84. PubMed ID: 21133243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Legal features of the drug advertising.
    Pashkov VM; Olefir AA; Bytyak OY
    Wiad Lek; 2017; 70(1):133-138. PubMed ID: 28343208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-European traditional herbal medicines in Europe: a community herbal monograph perspective.
    Qu L; Zou W; Zhou Z; Zhang T; Greef J; Wang M
    J Ethnopharmacol; 2014 Oct; 156():107-14. PubMed ID: 25169214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From DTCA-PD to patient information to health information: the complex politics and semantics of EU health policy.
    Brooks E; Geyer R
    J Eval Clin Pract; 2012 Dec; 18(6):1235-40. PubMed ID: 22816868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct-to-consumer advertising of prescription drugs: European Commission persists in putting industry's interests first.
    Prescrire Int; 2013 Jan; 22(134):24-5, 27. PubMed ID: 23373084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicinal products in the European Union--between harmonization and divergence.
    Lojko N
    Med Law; 2010 Mar; 29(1):61-76. PubMed ID: 22457998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EU health ministers reject proposal for limited direct to consumer advertising.
    Watson R
    BMJ; 2003 Jun; 326(7402):1284. PubMed ID: 12805139
    [No Abstract]   [Full Text] [Related]  

  • 10. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union.
    Vlietinck A; Pieters L; Apers S
    Planta Med; 2009 Jun; 75(7):683-8. PubMed ID: 19204891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New European commission regulation on variations to the terms of marketing authorization for medicinal products and its impact on Croatian legislation.
    Martinac AI; Tomić S; Simicić M
    Arh Hig Rada Toksikol; 2010 Sep; 61(3):311-22. PubMed ID: 20860972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of European Union legislation of herbal medicinal products and its transposition to national legislation in 1965-2007: case Finland.
    Koski SM; Laitinen-Parkkonen P; Airaksinen M
    Int J Health Plann Manage; 2015; 30(3):260-75. PubMed ID: 24375722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
    Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory status of medicinal products for human beings in the European Union. The role of generic products.
    Minghetti P
    Pharmacol Res; 1996; 34(1-2):3-7. PubMed ID: 8981548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative legal analysis of social media advertising of drugs in Germany and the United States.
    Buechner B
    Food Drug Law J; 2013; 68(3):259-79, i-ii. PubMed ID: 24640610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A contribution to the development of advertising in pharmacy II. Historical development of regulation of advertising of medicinal products].
    Vranová V
    Ceska Slov Farm; 2012 Oct; 61(5):240-3. PubMed ID: 23256658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing a European framework for research on children's medicines: an examination of the proposed EU regulation on medicinal products for paediatric use.
    Seyberth HW; Demotes-Mainard J; Wrobel P
    Pediatr Nephrol; 2005 Nov; 20(11):1537-40. PubMed ID: 16167134
    [No Abstract]   [Full Text] [Related]  

  • 18. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
    Lehmann B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restrictions on the conduct of advertising of medicinal products in Poland and their violations.
    Czerw A; Marek EM
    Acta Pol Pharm; 2013; 70(4):769-76. PubMed ID: 23923402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promotion of prescription drugs to consumers.
    Rosenthal MB; Berndt ER; Donohue JM; Frank RG; Epstein AM
    N Engl J Med; 2002 Feb; 346(7):498-505. PubMed ID: 11844852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.